title: Development of taxane-containing chemotherapy of doxorubicin-resistant diffuse large B-cell lymphoma.
abstract: Recurrent diffuse large B-cell lymphoma (DLBCL) presents a significant challenge in the clinic, which necessitates the development of alternative therapeutic regimens. Here, we quantified the growth inhibition rate of a panel of clinically approved anticancer drugs in a patient-derived DLBCL cell line that is resistant to doxorubicin, a central component of the standard of care R-CHOP. Our study indicates that this cell line is especially sensitive to two taxanes, docetaxel and paclitaxel. Furthermore, the effective dose of taxane can be lowered when it is combined with other anticancer drugs. Our study provides guidance for preclinical studies to test alternative regimens for recurrent DLBCL.
authors.affiliation: aDepartment of Oncology, People's Hospital of Guizhou Province, Guiyang bDepartment of Haematology, Guiyang College of Medicine, Guiyang, People's Republic of China.
authors.forename: Li
authors.initials: L
authors.lastname: Wu
authors.forename: Jishi
authors.initials: J
authors.lastname: Wang
authors.forename: Yong
authors.initials: Y
authors.lastname: Li
authors.forename: Li
authors.initials: L
authors.lastname: Zuo
authors.forename: Zhiming
authors.initials: Z
authors.lastname: Zhang
authors.forename: Jinlin
authors.initials: J
authors.lastname: Ouyang
authors.forename: Jianmin
authors.initials: J
authors.lastname: Fan
authors.forename: Hang
authors.initials: H
authors.lastname: Li
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D000077143:Docetaxel; D004317:Doxorubicin / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D004357:Drug Synergism; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D017239:Paclitaxel / Q000494:pharmacology; D043823:Taxoids / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin; D017239:Paclitaxel